MetaCap

Purple Biotech (PPBT) vs Redhill Biopharma (RDHL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Redhill Biopharma is the larger company by market cap ($2.5 million vs $1.9 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PPBT+4.45%RDHL-40.72%
+25%-9%-44%
Oct 7, 20261 yearNov 20, 2026
PPBT+14.66%RDHL-47.87%
+26%-13%-51%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PPBT versus RDHL key metrics
MetricPPBTRDHL
Share price$1.53$0.281
Market cap$1.86M$2.50M
1-day change-4.09%-13.08%
Forward P/E—9.37
EPS (TTM)$-47.64$0.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$8.04M
Revenue growth (YoY)—+23.17%
Net income (latest FY)$-26.39M$-8.27M
Gross margin—60.31%
Operating margin—-181.69%
Net margin—-102.80%
52-week high$8.90$1.60
52-week low$0.91$0.281
Distance from 52-week high-82.87%-82.44%
Analyst consensusnone—
Avg. price target upside+1014.75%—
Average volume1.26M2.08M
Shares outstanding1.22M8.89M
Employees1013
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Purple Biotech

PPBT stock →

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About Redhill Biopharma

RDHL stock →

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

PPBT vs RDHL FAQ

Which is bigger, Purple Biotech or Redhill Biopharma?

Redhill Biopharma (RDHL) is larger, with a market capitalization of $2.50M compared with $1.86M for Purple Biotech (PPBT).

Are Purple Biotech and Redhill Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons